medinfoАктуальные проблемы теоретической и клинической медициныActual Problems of Theoretical and Clinical Medicine2790-12892790-1297Казахстанско-Российский медицинский университет10.24412/2790-1289-2023-1-93-98medinfo-297Research ArticleОБЗОР ЛИТЕРАТУРЫREVEWSЭВОЛЮЦИЯ ЛЕЧЕНИЯ ТУБЕРКУЛЕЗА В ИНДИИ ОТ САНАТОРНО КУРОРТНОГО ЛЕ ЧЕНИЯ К ПЕРСОНАЛИЗИРОВАННОЙ МЕДИЦИНЕTHE EVOLUTION OF TUBERCULOSIS TREATMENT IN INDIA FROM SANATORIUMS TO PERSONALIZED MEDICINEhttps://orcid.org/0000-0003-2724-2328SinghA.SinghA.

Aryan Singh, студент 2 курса, Факультета «Общая медицина»

Алматы

Aryan Singh, 2nd year of student, Faculty of General Medicine

Almaty

nauka@medkrmu.kzНУО «Казахстанско-Российский медицинский университет»КазахстанNEI «Kazakh-Russian Medical University»Kazakhstan202327042023019398Copyright © Singh A., 20232023Singh A.Singh A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://kazrosmedjournal.krmu.edu.kz/jour/article/view/297

Туберкулез (ТБ) – тяжелое инфекционное заболевание, поражающее людей на протяжении веков. Лечение туберкулеза значительно эволюционировало с годами: от использования санаториев в качестве основного метода лечения до внедрения антибиотиков и появления персонализированной медицины. Санатории были популярны в конце 19 - начале 20 веков, но их доступность и стоимость были ограничены. Открытие и разработка антибиотиков, таких как стрептомицин и изониазид, привели к широкому внедрению антибиотиков в качестве основного средства лечения туберкулеза. Персонализированная медицина — это новый подход, ориентированный на конкретные потребности каждого пациента посредством генотипирования и индивидуальных схем лечения. Будущее лечения туберкулеза может заключаться в индивидуальных подходах. Данная статья представляет собой обзор литературы по указанной теме на основе тематических исследований.

Tuberculosis (TB) is a serious infectious disease that has affected humans for centuries. The treatment of TB has evolved significantly over the years, from the use of sanatoriums as the primary treatment method to the introduction of antibiotics and the emergence of personalized medicine. Sanatoriums were popularized in the late 19th and early 20th centuries but were limited in their accessibility and cost. The discovery and development of antibiotics, such as streptomycin and isoniazid, led to the widespread adoption of antibiotics as the primary treatment for TB. Personalized medicine is a new approach that targets the specific needs of each patient through genotyping and individualized drug regimens. The future of TB treatment may lie in individualized, personalized approaches. This article is a literature review on the mentioned topic based on Case Studies.

туберкулез (ТБ)санаторииизониазидвакцинаНИСТtuberculosissanatoriumsisoniazidvaccinesNTEPReferencesWorld Health Organization (WHO). Global Tuberculosis Report 2021. https://www.who.int/publications/i/item/9789240037021.World Health Organization (WHO). Global Tuberculosis Report 2021. https://www.who.int/publications/i/item/9789240037021.Migliori G.B., Sotgiu G., Gandhi N.R., et al. Drug resistance in tuberculosis. Cold Spring Harbor perspectives in medicine, 2015, 5(9), a017800. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556232/.Migliori G.B., Sotgiu G., Gandhi N.R., et al. Drug resistance in tuberculosis. Cold Spring Harbor perspectives in medicine, 2015, 5(9), a017800. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556232/.Zumla A., George A., Sharma V., et al. The WHO 2014 Global tuberculosis report—further to go. The Lancet Global Health, 2015, 3(1), e10-e12. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(14)70361-4/fulltext.Zumla A., George A., Sharma V., et al. The WHO 2014 Global tuberculosis report—further to go. The Lancet Global Health, 2015, 3(1), e10-e12. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(14)70361-4/fulltext.World Health Organization (WHO). Treatment of Tuberculosis: Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update. https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/.World Health Organization (WHO). Treatment of Tuberculosis: Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update. https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/.Johnson J.L., Neumann G., MacKenzie T., et al. Optimizing treatment for drug-resistant tuberculosis. PLoS medicine, 2006, 3 (3), e120. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0030120.Johnson J.L., Neumann G., MacKenzie T., et al. Optimizing treatment for drug-resistant tuberculosis. PLoS medicine, 2006, 3 (3), e120. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0030120.Centers for Disease Control and Prevention (CDC). Treatment of Tuberculosis. CDC, 2022. https://www.cdc.gov/tb/topic/treatment/default.htm.Centers for Disease Control and Prevention (CDC). Treatment of Tuberculosis. CDC, 2022. https://www.cdc.gov/tb/topic/treatment/default.htm.World Health Organization (WHO). The End TB Strategy. WHO, 2015. https://www.who.int/tb/post2015_strategy/en/.World Health Organization (WHO). The End TB Strategy. WHO, 2015. https://www.who.int/tb/post2015_strategy/en/.

The authors declare that there are no conflicts of interest present.